<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-86910" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Management of Antithrombotics Around Gastrointestinal Procedures</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gnanapandithan</surname>
            <given-names>Karthik</given-names>
          </name>
          <aff>Yale-New Haven Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Muniraj</surname>
            <given-names>Thiruvengadam</given-names>
          </name>
          <aff>Yale University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karthik Gnanapandithan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thiruvengadam Muniraj declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-86910.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Antiplatelets and anticoagulants are used to reduce the risk of venous thromboembolism in patients at high risk. However, when these patients need gastrointestinal procedures like endoscopy, these agents increased the risk of bleeding related to the procedure. This activity reviews an interprofessional approach to holding antithrombotic therapy before different gastrointestinal procedures, and the resumption following the same.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the risk of bleeding associated with different gastrointestinal procedures.</p></list-item><list-item><p>Summarize the risks of thromboembolism in different medical conditions.</p></list-item><list-item><p>Describe the approach to the management of anticoagulants and antiplatelets before elective gastrointestinal procedures.</p></list-item><list-item><p>Outline the approach to managing the risks of bleeding associated with antithrombotic agents in patients requiring emergent endoscopy by an interprofessional team.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=86910&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=86910">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-86910.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Antithrombotic therapy, including antiplatelet and anticoagulants, is used to reduce the risk of thromboembolic episodes in patients with medical conditions like coronary artery disease (CAD), cerebrovascular accidents (CVA), peripheral arterial disease (PAD), atrial fibrillation (AF), venous thromboembolism (VTE), hypercoagulable states, and mechanical heart valves among others. These agents increase the bleeding risk when undertaking endoscopic procedures, but there is also a risk of thromboembolic sequelae if they are withheld. The strategy for managing this therapy when these patients need gastrointestinal (GI) endoscopic procedures has been a subject of controversy. In this chapter, we discuss this based on the available evidence and the current guidelines.<xref ref-type="bibr" rid="article-86910.r1">[1]</xref><xref ref-type="bibr" rid="article-86910.r2">[2]</xref><xref ref-type="bibr" rid="article-86910.r3">[3]</xref>&#x000a0;The two vital factors to be considered while performing an endoscopic procedure in a patient on these agents is the risk of bleeding associated with the procedure and the risk of thromboembolism associated with the underlying medical condition for which the agents are being used.</p>
      </sec>
      <sec id="article-86910.s3" sec-type="Function">
        <title>Function</title>
        <p>
<bold>Bleeding Risk Associated With The Procedure</bold>
</p>
        <p>Various endoscopic procedures have different risks of associated bleeding. The table&#x000a0;lists the general risks of bleeding among the commonly employed endoscopic procedures.<xref ref-type="bibr" rid="article-86910.r1">[1]</xref>&#x000a0;See <bold>Table.</bold> Bleeding Risk Associated With Endoscopic Procedures. Most of the data is from studies conducted in patients who are not on multiple antithrombotic agents, and hence this needs to be interpreted with caution in an individual patient. Traditionally, endoscopic procedures associated with intervention have a higher bleeding risk than those without interventions. Other factors influence this risk, as well. For example, polypectomy, one of the most common interventions during endoscopy, has a bleeding risk ranging from 0.3% to 10%, depending on poly size, location, type of polyp, and the technique for resection or cautery used. Percutaneous endoscopic gastrostomy (PEG) in patients on a single antiplatelet therapy is considered low risk, whereas a percutaneous endoscopic jejunostomy (PEJ) in general has a higher risk of bleeding. Endoscopic submucosal dissection and endoscopic resection of large (greater than 2 cm) polyps are considered ultra-high risk procedures.<xref ref-type="bibr" rid="article-86910.r3">[3]</xref></p>
        <p>
<bold>Thrombosis Risk Associated With The Condition </bold>
</p>
        <p>The underlying condition dictates the risk of thromboembolic episodes in these patients, especially when withholding the antithrombotic agent. Stroke prevention in non-valvular AF is a very common indication for antiplatelet or anticoagulant therapy, and the risk of cerebral thromboembolism in these patients is predictable using the CHA(2)DS(2)Vasc index.<xref ref-type="bibr" rid="article-86910.r4">[4]</xref>&#x000a0;This measure includes&#x000a0;congestive heart failure, hypertension, age greater than or equal to 75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category; age greater than or equal to 75 years, and previous stroke carry doubled risk weight. In patients with CAD on antiplatelet therapy, a few important factors determine the risk of major adverse cardiac events. Placement of a drug-eluting coronary stent (DES) in the last 12 months or a bare-metal stent (BMS) within one month or an acute coronary syndrome (ACS) within six months are considered high-risk conditions requiring dual antiplatelet therapy (DAPT).<xref ref-type="bibr" rid="article-86910.r5">[5]</xref>&#x000a0;Patients on anticoagulation for venous thromboembolism (VTE) or mechanical heart valves have different risk factors for thromboembolic episodes. As shown in the table, the patients were categorized as low, medium, and high-risk groups.<xref ref-type="bibr" rid="article-86910.r5">[5]</xref>&#x000a0;Bioprosthetic valves are considered low risk. See&#x000a0;<bold>Table.</bold> Thromboembolic Episode Risks.&#x000a0;</p>
      </sec>
      <sec id="article-86910.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Interruption of Antithrombotic Therapy&#x000a0;Before Endoscopy</bold>
</p>
        <p>
<bold>Elective Endoscopy</bold>
</p>
        <p>In patients who need elective endoscopic procedures, if the indication for anti-thrombotic therapy is short-term, the procedure is best delayed until after that period. For patients on long-term or life-long antithrombotic treatment, the decision to temporarily hold the treatment for endoscopy should occur after a discussion with the patient and the concerned providers (primary medical provider, cardiologist, neurologist, or hematologist). In some high-risk patients, these agents cannot be interrupted, in which case the surgeon and patient must consider the risks and benefits of the procedure. See <bold>Figures.</bold> Anticoagulant Therapy and Antiplatelet Therapy Before Elective Endoscopic Procedures.</p>
        <p>
<bold>Parenteral anticoagulants</bold>
</p>
        <p>Unfractionated heparin (UHF) administered as a continuous intravenous infusion can be stopped 3 to 4 hours before the procedure, given the short half-life. Low molecular weight heparin (LMWH), including enoxaparin and dalteparin, should be stopped 24 hours prior to the procedure.<xref ref-type="bibr" rid="article-86910.r2">[2]</xref><xref ref-type="bibr" rid="article-86910.r6">[6]</xref>&#x000a0;Fondaparinux is a synthetic X-a inhibitor that requires discontinuation at least 36 hours preceding a high-risk procedure.</p>
        <p>
<bold>Warfarin</bold>
</p>
        <p>The therapeutic effect of warfarin is measured in terms of the International Normalized Ratio (INR). The INR decreases to less than 1.5 in over 90% of patients when holding treatment is held for five days.<xref ref-type="bibr" rid="article-86910.r7">[7]</xref>&#x000a0;The overall risk of a thromboembolic event when warfarin for 4 to 7 days is around 1%.<xref ref-type="bibr" rid="article-86910.r8">[8]</xref>&#x000a0;Hence it is recommended that warfarin is restarted within 4 to 7 days of initial discontinuation to keep the risk of these events to a minimum.<xref ref-type="bibr" rid="article-86910.r1">[1]</xref>&#x000a0;The role of bridge therapy with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) has been studied for patients on warfarin for various indications. Based on the current guidelines for patients with valvular AF on warfarin, bridging is recommended for a CHA(2)DS(2)Vasc score of 2 or more. LMWH should be started two days after discontinuation of warfarin therapy, and the last dose should be administered at least 24 hours before the procedure.<xref ref-type="bibr" rid="article-86910.r2">[2]</xref>&#x000a0;Those with a CHA(2)DS(2)Vasc score of 0 or 1 do not require bridge therapy while withholding warfarin. Another study&#x000a0;showed that bridge therapy for nonvalvular AF in the periprocedural period was associated with higher bleeding risk and no benefit in reducing thromboembolic episodes. However, these studies should require cautious interpretation with caution in patients with a higher risk of thrombosis.<xref ref-type="bibr" rid="article-86910.r9">[9]</xref> In these patients, bridge therapy is always recommended using an interprofessional approach with the other providers managing anticoagulation therapy.</p>
        <p>
<bold>Direct Oral Anticoagulants</bold>
</p>
        <p>The use of direct oral anticoagulants (DOACs) has been on the rise over the last decade. This trend includes anti-Xa agents, rivaroxaban and apixaban, and the direct thrombin inhibitor dabigatran. There are no reliable laboratory assays to assess the anticoagulant effect of these agents at this time. The duration before high-risk endoscopic procedures that the DOACs have to be held depends on the patient's renal function. The anti-Xa drugs should be held for 1&#x000a0;to 2 days if the creatinine clearance (CrCl)is 60 mL/min or more, for three days if the CrCl is between 30 mL/min and 59 mL/min, and for four days if the CrCl is less than 30 mL/min.<xref ref-type="bibr" rid="article-86910.r10">[10]</xref>&#x000a0;The recommendation for stopping dabigatran is 2&#x000a0;to 3 days before a high-risk procedure in patients with CrCl more than 80 mL/min, 3&#x000a0;to 4 days prior if between 30&#x000a0;to 49 mL/min, and 4&#x000a0;to 6 days prior if less than 30 mL/min.<xref ref-type="bibr" rid="article-86910.r11">[11]</xref></p>
        <p>
<bold>Antiplatelets</bold>
</p>
        <p>Aspirin and thienopyridines (clopidogrel, prasugrel, and ticagrelor) are the most commonly used antiplatelet agents. Aspirin irreversibly inhibits cyclooxygenase systems. It takes 7 to 9 days to regain platelet function following the discontinuation of aspirin.<xref ref-type="bibr" rid="article-86910.r12">[12]</xref>&#x000a0;Thienopyridines inhibit platelet aggregation by binding to the P2Y12 component of the platelet ADP receptors. Clopidogrel and prasugrel have to be stopped 5 to 7 days prior to allow normal platelet aggregation to resume as opposed to ticagrelor, a reversible P2Y12 inhibitor that can be stopped 3&#x000a0;to 5 days prior.<xref ref-type="bibr" rid="article-86910.r13">[13]</xref>&#x000a0;In patients on dual antiplatelet therapy with aspirin and a thienopyridine, research has shown that those who discontinued both had a much higher incidence of stent thrombosis than those who remained on aspirin alone.<xref ref-type="bibr" rid="article-86910.r14">[14]</xref>&#x000a0;The recommendation for patients on antiplatelet therapy undergoing high-risk endoscopic procedures is the continue the aspirin and stop the thienopyridine agent 5 to 7 days before the procedure.<xref ref-type="bibr" rid="article-86910.r1">[1]</xref></p>
        <p>
<bold>Emergent Endoscopy</bold>
</p>
        <p>The most common indication for emergent endoscopic procedures is GI bleeding. The common etiologies for acute upper GI bleeding are peptic ulcer disease, variceal bleeding, and gastritis or esophagitis, while lower GI bleeding is most commonly diverticular in origin. The decision to discontinue antithrombotic therapy and reversal of anticoagulation must be weighed against the risk of incurring a thromboembolic event. Correction of INR to between 1.5 and 2.5 is adequate for diagnostic and intervention purposes and is comparable to patients not on any form of anticoagulation. Therapeutic measures to achieve hemostasis in patients with GI bleeding are effective even with a moderately elevated INR.<xref ref-type="bibr" rid="article-86910.r15">[15]</xref><xref ref-type="bibr" rid="article-86910.r16">[16]</xref>&#x000a0;Hence it is not advisable to delay the procedure until the normalization of INR. In patients with acute bleeding, warfarin can be held, and the reversal of anticoagulation is most rapidly achieved with 4-factor prothrombin complex concentrate (PCC) when compared to fresh frozen plasma (FFP).<xref ref-type="bibr" rid="article-86910.r17">[17]</xref>&#x000a0;Vitamin K can be given intravenously as an additional therapy at a dose of 5 mg or 10 mg. In patients with mechanical heart valves requiring reversal of anticoagulation, either FFP or PCC are options.<xref ref-type="bibr" rid="article-86910.r18">[18]</xref>&#x000a0;High-dose vitamin K therapy is generally not preferred in these patients as it can increase the coagulability for a longer period.</p>
        <p>If an urgent reversal of anticoagulation is necessary for patients on UFH therapy, they can receive a slow infusion of protamine sulfate. The dose is calculated based on the dose of heparin administered and the duration of therapy. The anticoagulant effect of dabigatran is reversible with idarucizumab. Idarucizumab is approved for life-threatening bleeding or before emergent surgery.<xref ref-type="bibr" rid="article-86910.r19">[19]</xref>&#x000a0;Since the kidneys primarily excrete it, hemodialysis is also a viable option in these patients. Andexanet alfa is a recombinant modified factor X-a protein that acts as a specific antidote for direct thrombin inhibitors, low molecular weight heparin, and fondaparinux.<xref ref-type="bibr" rid="article-86910.r20">[20]</xref>&#x000a0;For patients on antiplatelet therapy with acute major bleeding, the options include stopping the agent and/or reversal by platelet administration, which merits consideration with the thrombotic risk in an individual patient.</p>
        <p>
<bold>Resumption Of Antithrombotic Therapy After Endoscopy</bold>
</p>
        <p>Anticoagulation should generally be resumed upon completion of the procedure unless there remains a continued risk of major bleeding.<xref ref-type="bibr" rid="article-86910.r1">[1]</xref><xref ref-type="bibr" rid="article-86910.r6">[6]</xref>&#x000a0;This concept has its basis in studies available on warfarin and heparin products, with minimal literature available regarding the resumption of DOACs. For patients on warfarin with a high risk of thromboembolism, the recommendation is for UFH or LMWH to be started at the earliest possible when there is no risk of major bleeding and continued until INR reaches a therapeutic level with warfarin. For patients at a lower risk of thromboembolism, warfarin should be restarted within 24 hours of the procedure. Because of the shorter duration of DOACs, if treatment with these agents cannot resume within 24 hours of a high-risk procedure, bridge therapy should be considered with UFH or LMWH in patients with a high risk of thrombosis.<xref ref-type="bibr" rid="article-86910.r21">[21]</xref>&#x000a0;In patients receiving DOACs for stroke prophylaxis in AF, the use of these agents can safely resume one day after low-risk procedures and 2&#x000a0;to 3 days after high-risk procedures without the need for bridging.<xref ref-type="bibr" rid="article-86910.r22">[22]</xref>&#x000a0;All antiplatelet agents should resume soon after hemostasis.</p>
      </sec>
      <sec id="article-86910.s5" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>It is essential for health care providers to educate patients on the importance of holding these medications for the specific duration before the procedure and on their prompt resumption. This counsel is possible through direct counseling, educational materials, and the use of technology to send reminders. The potential risks and benefits of this strategy have to be discussed with patients by the interprofessional team.&#x000a0;This interprofessional approach is vital in ensuring an appropriate treatment plan.&#x000a0;In addition to the specialists, surgeons, and other clinicians, nursing will monitor the patient following the procedure. A board-certified pharmacotherapy pharmacist can consult with the clinicians to stop and resume anticoagulation therapy surrounding the procedure.</p>
        <p>A patient-centered interprofessional team consisting of the primary care provider, gastroenterologist, cardiologist, or hematologist, pharmacists, and nurses have to be involved in guiding patients on handling the change in their medication regimen, monitoring for bleeding, titration of therapy, and early recognition of any complications should they occur.&#x000a0;This team paradigm will positively drive patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-86910.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=86910&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=86910">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/86910/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=86910">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-86910.s7">
        <fig id="article-86910.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Bleeding Risk Associated With Endoscopic Procedures. The table shows the bleeding&#x000a0;risk associated with the various common endoscopic procedures. Acosta RD, Abraham NS; ASGE Standards of Practice Committee, et al.&#x000a0;The management of antithrombotic agents for patients undergoing GI endoscopy. <italic toggle="yes">Gastrointest Endosc.</italic> 2016;83(1):p3-p16. Doi: 10.1016/j.gie.2015.09.035.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Bleeding__Risk" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-86910.s8">
        <fig id="article-86910.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Thromboembolic Episode Risks. The table shows the risk of thromboembolism in patients on anticoagulation for mechanical heart valves or venous thromboembolism. Adapted&#x000a0;from Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012;141(2 suppl):e326S-e350S. doi: 10.1378/chest.11-2298.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Thromboembolic__Episode" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-86910.s9">
        <fig id="article-86910.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Anticoagulant Therapy Before Elective Endoscopic Procedures. This figure depicts the management of anticoagulant therapy before elective endoscopic procedures. Adapted from Veitch AM, Vanbiervliet G, Gershlick AH, et al.&#x000a0;Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.&#x000a0;<italic toggle="yes">Endoscopy.</italic> 2016;48:1-18. doi:&#x000a0;10.1055/s-0042-102652.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Anticoagulant__Therapy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-86910.s10">
        <fig id="article-86910.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Antiplatelet Therapy Before&#x000a0;Elective Endoscopic Procedures. This figure depicts the management of antiplatelet therapy before elective endoscopic procedures. Adapted from Veitch AM, Vanbiervliet G, Gershlick AH, et al.&#x000a0;Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.&#x000a0;Endoscopy.&#x000a0;2016;48:1-18. doi:&#x000a0;10.1055/s-0042-102652.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Antiplatelet__Therapy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-86910.s11">
        <title>References</title>
        <ref id="article-86910.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>ASGE Standards of Practice Committee</collab>
              <name>
                <surname>Acosta</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Chandrasekhara</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chathadi</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Early</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Eloubeidi</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Faulx</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Fonkalsrud</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Khashab</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lightdale</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Muthusamy</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Pasha</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Saltzman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Shaukat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shergill</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cash</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>DeWitt</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The management of antithrombotic agents for patients undergoing GI endoscopy.</article-title>
            <source>Gastrointest Endosc</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-16</page-range>
            <pub-id pub-id-type="pmid">26621548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veitch</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vanbiervliet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gershlick</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Boustiere</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baglin</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Radaelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gralnek</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dumonceau</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.</article-title>
            <source>Endoscopy</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>c1</fpage>
            <pub-id pub-id-type="pmid">28114689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>FKL</given-names>
              </name>
              <name>
                <surname>Goh</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Hokimoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kitazono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Mahachai</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tsoi</surname>
                <given-names>KKF</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Sugano</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines.</article-title>
            <source>Gut</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>405</fpage>
            <page-range>405-417</page-range>
            <pub-id pub-id-type="pmid">29331946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Nieuwlaat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pisters</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Crijns</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.</article-title>
            <source>Chest</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>137</volume>
            <issue>2</issue>
            <fpage>263</fpage>
            <page-range>263-72</page-range>
            <pub-id pub-id-type="pmid">19762550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Douketis</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Spyropoulos</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Mayr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jaffer</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Eckman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Kunz</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e326S</fpage>
            <page-range>e326S-e350S</page-range>
            <pub-id pub-id-type="pmid">22315266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwok</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Faigel</surname>
                <given-names>DO</given-names>
              </name>
            </person-group>
            <article-title>Management of anticoagulation before and after gastrointestinal endoscopy.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>104</volume>
            <issue>12</issue>
            <fpage>3085</fpage>
            <page-range>3085-97; quiz 3098</page-range>
            <pub-id pub-id-type="pmid">19672250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schulman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Elbazi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zondag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study.</article-title>
            <source>Thromb J</source>
            <year>2008</year>
            <month>Oct</month>
            <day>16</day>
            <volume>6</volume>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">18925967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Regan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Henault</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Upadhyay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Othman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hylek</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Risk of thromboembolism with short-term interruption of warfarin therapy.</article-title>
            <source>Arch Intern Med</source>
            <year>2008</year>
            <month>Jan</month>
            <day>14</day>
            <volume>168</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-9</page-range>
            <pub-id pub-id-type="pmid">18195197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Douketis</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Spyropoulos</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Kaatz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Caprini</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaffer</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turpie</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Hasselblad</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
              <collab>BRIDGE Investigators</collab>
            </person-group>
            <article-title>Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Aug</month>
            <day>27</day>
            <volume>373</volume>
            <issue>9</issue>
            <fpage>823</fpage>
            <page-range>823-33</page-range>
            <pub-id pub-id-type="pmid">26095867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubois</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dincq</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Douxfils</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ickx</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Samama</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Dogn&#x000e9;</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gourdin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chatelain</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mullier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lessire</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Perioperative management of patients on direct oral anticoagulants.</article-title>
            <source>Thromb J</source>
            <year>2017</year>
            <volume>15</volume>
            <fpage>14</fpage>
            <pub-id pub-id-type="pmid">28515674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Quinlan</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Periprocedural management and approach to bleeding in patients taking dabigatran.</article-title>
            <source>Circulation</source>
            <year>2012</year>
            <month>Nov</month>
            <day>13</day>
            <volume>126</volume>
            <issue>20</issue>
            <fpage>2428</fpage>
            <page-range>2428-32</page-range>
            <pub-id pub-id-type="pmid">23147769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patrono</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ciabattoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Patrignani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pugliese</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Filabozzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Catella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dav&#x000ec;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Forni</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology of platelet cyclooxygenase inhibition.</article-title>
            <source>Circulation</source>
            <year>1985</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>1177</fpage>
            <page-range>1177-84</page-range>
            <pub-id pub-id-type="pmid">3933848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurbel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bliden</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tantry</surname>
                <given-names>US</given-names>
              </name>
              <name>
                <surname>Gesheff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Antonino</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Karunakaran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kereiakes</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Parris</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Purdy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ledley</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Storey</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.</article-title>
            <source>Circulation</source>
            <year>2009</year>
            <month>Dec</month>
            <day>22</day>
            <volume>120</volume>
            <issue>25</issue>
            <fpage>2577</fpage>
            <page-range>2577-85</page-range>
            <pub-id pub-id-type="pmid">19923168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eisenberg</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Libersan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Filion</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents.</article-title>
            <source>Circulation</source>
            <year>2009</year>
            <month>Mar</month>
            <day>31</day>
            <volume>119</volume>
            <issue>12</issue>
            <fpage>1634</fpage>
            <page-range>1634-42</page-range>
            <pub-id pub-id-type="pmid">19289638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Murdoch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes.</article-title>
            <source>Gastrointest Endosc</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>369</fpage>
            <page-range>369-73</page-range>
            <pub-id pub-id-type="pmid">14528210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shingina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barkun</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Razzaghi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bardou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gralnek</surname>
                <given-names>I</given-names>
              </name>
              <collab>RUGBE Investigators</collab>
            </person-group>
            <article-title>Systematic review: the presenting international normalised ratio (INR) as a predictor of outcome in patients with upper nonvariceal gastrointestinal bleeding.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2011</year>
            <month>May</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>1010</fpage>
            <page-range>1010-8</page-range>
            <pub-id pub-id-type="pmid">21385193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holbrook</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Vandvik</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Veenstra</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e152S</fpage>
            <page-range>e152S-e184S</page-range>
            <pub-id pub-id-type="pmid">22315259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Carabello</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Jneid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Rigolin</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular&#x000a0;Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>11</day>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>252</fpage>
            <page-range>252-289</page-range>
            <pub-id pub-id-type="pmid">28315732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pollack</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Glund</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verhamme</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Dubiel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huisman</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Hylek</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kamphuisen</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Kreuzer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sellke</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Stangier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Idarucizumab for Dabigatran Reversal.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Aug</month>
            <day>06</day>
            <volume>373</volume>
            <issue>6</issue>
            <fpage>511</fpage>
            <page-range>511-20</page-range>
            <pub-id pub-id-type="pmid">26095746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connolly</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Curnutte</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bronson</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Conley</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Verhamme</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Beyer-Westendorf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Albaladejo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lopez-Sendon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Demchuk</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pallin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Concha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leeds</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siegal</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Zotova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meeks</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakamya</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Milling</surname>
                <given-names>TJ</given-names>
              </name>
              <collab>ANNEXA-4 Investigators</collab>
            </person-group>
            <article-title>Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Apr</month>
            <day>04</day>
            <volume>380</volume>
            <issue>14</issue>
            <fpage>1326</fpage>
            <page-range>1326-1335</page-range>
            <pub-id pub-id-type="pmid">30730782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uedo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hokimoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ieko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Higuchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment: 2017 Appendix&#x000a0;on Anticoagulants Including Direct Oral Anticoagulants.</article-title>
            <source>Dig Endosc</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>433</fpage>
            <page-range>433-440</page-range>
            <pub-id pub-id-type="pmid">29733468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86910.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Douketis</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Spyropoulos</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carrier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Gal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tafur</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Vanassche</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Verhamme</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shivakumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AYY</given-names>
              </name>
              <name>
                <surname>Yeo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Solymoss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kassis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Le Templier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blostein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>MacKay</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Arnaoutoglou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Coppens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Caprini</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moffat</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant.</article-title>
            <source>JAMA Intern Med</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>179</volume>
            <issue>11</issue>
            <fpage>1469</fpage>
            <page-range>1469-1478</page-range>
            <pub-id pub-id-type="pmid">31380891</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
